Literature DB >> 29386609

Immunotherapy: Oncolytic virotherapy enables checkpoint blockade.

Sarah Crunkhorn.   

Abstract

Year:  2018        PMID: 29386609     DOI: 10.1038/nrd.2018.11

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  2 in total

1.  Neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer to immune checkpoint therapy.

Authors:  Marie-Claude Bourgeois-Daigneault; Dominic Guy Roy; Amelia Sadie Aitken; Nader El Sayes; Nikolas Tim Martin; Oliver Varette; Theresa Falls; Lauren Elizabeth St-Germain; Adrian Pelin; Brian Dennis Lichty; David Francis Stojdl; Guy Ungerechts; Jean-Simon Diallo; John Cameron Bell
Journal:  Sci Transl Med       Date:  2018-01-03       Impact factor: 17.956

2.  Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade.

Authors:  Adel Samson; Karen J Scott; David Taggart; Emma J West; Erica Wilson; Gerard J Nuovo; Simon Thomson; Robert Corns; Ryan K Mathew; Martin J Fuller; Timothy J Kottke; Jill M Thompson; Elizabeth J Ilett; Julia V Cockle; Philip van Hille; Gnanamurthy Sivakumar; Euan S Polson; Samantha J Turnbull; Elizabeth S Appleton; Gemma Migneco; Ailsa S Rose; Matthew C Coffey; Deborah A Beirne; Fiona J Collinson; Christy Ralph; D Alan Anthoney; Christopher J Twelves; Andrew J Furness; Sergio A Quezada; Heiko Wurdak; Fiona Errington-Mais; Hardev Pandha; Kevin J Harrington; Peter J Selby; Richard G Vile; Stephen D Griffin; Lucy F Stead; Susan C Short; Alan A Melcher
Journal:  Sci Transl Med       Date:  2018-01-03       Impact factor: 17.956

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.